Article
IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.
Haematologica - 1 May 2026
Hoff Fieke W, Huang Ying, Welkie Rina Li, Swords Ronan T, Traer Elie, Stein Eytan M, Lin Tara L, Baer Maria R, Duong Vu H, Blum William G, Arellano Martha L, Stock Wendy, Odenike Olatoyosi, Zeidner Joshua F, Olin Rebecca L, Smith Catherine C, Schiller Gary J, Curran Emily K, Handa Shivani V, Heerema Nyla A, Chen Timothy, Martycz Molly, Stefanos Mona, Marcus Sonja G, Rosenberg Leonard, Druker Brian J, Levine Ross L, Burd Amy, Yocum Ashley O, Borate Uma M, Mims Alice S, Byrd John C, Madanat Yazan F
Abstract excerpt
Mutations of isocitrate dehydrogenase (IDH) are recurrent in newly diagnosed acute myeloid leukemia (AML) and their prevalence increases with age. The prognostic impact of IDH mutations in AML remains controversial. IDH inhibitors generally have a favorable side-effect profile, making them an attractive option for older patients. This retrospective analysis aimed to describe the prevalence and prognostic impact...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.